JNJ Johnson and Johnson

By Colin Kellaher

Johnson & Johnson on Wednesday said the European Commission approved the Ebola vaccine regimen from its Janssen Pharmaceutical Cos. unit for the prevention of the disease caused by the Zaire ebolavirus species in individuals ages one and older.

J&J said Janssen is now collaborating with the World Health Organization on vaccine pre-qualification, which it said should help accelerate registration of the regimen in African countries and facilitate broader access to those most in need.

The regimen includes Ad26.ZEBOV, based on Janssen's proprietary AdVac viral vector technology, as the first dose, and MVA-BN-Filo, based on Bavarian Nordic A/S's MVA-BN technology, as a second dose administered roughly eight weeks later.

The second-deadliest Ebola outbreak in history, which began in the Democratic Republic of the Congo in 2018, has infected nearly 3,500 people, killing nearly 2,300 of them.

J&J said a WHO advisory group last year recommended the use of Janssen's Ebola vaccine regimen as part of efforts to contain the outbreak, adding that more than 50,000 people in Congo and Rwanda have been vaccinated to date through the initiative.

J&J noted that the approval marks the first major regulatory nod for a vaccine developed by Janssen.

Write to Colin Kellaher at colin.kellaher@wsj.com

(END) Dow Jones Newswires

July 01, 2020 10:08 ET (14:08 GMT)

Johnson and Johnson (NYSE:JNJ)
Graphique Historique de l'Action
De Mar 2024 à Avr 2024

Johnson and Johnson (NYSE:JNJ)
Graphique Historique de l'Action
De Avr 2023 à Avr 2024